EMVision Medical Devices Limited has established its pilot commercial production line and received a $1.25 million non-dilutive cash payment under the Modern Manufacturing Initiative (MMI) grant program.
This achievement marks a significant milestone for the company as it progresses towards large-scale production of its innovative emu point-of-care brain scanner, the company said in an ASX announcement.
The Australian Government awarded EMVision $5 million in non-dilutive funding through the MMI Medical Products Translation stream.
This funding supports the commercial production of the emu brain scanner, a cutting-edge device designed to revolutionise point-of-care brain imaging.
The newly established production line at EMVision’s Macquarie Park premises is currently capable of building, testing, and releasing approximately one emu brain scanner per week.
With minor staffing increases, this capacity can expand to up to three units per week, underlining the scalability of the production process.
Founded in 2017, EMVision Medical Devices is an Australian medical device company developing a novel approach to looking inside the human body.
Its product pipeline includes portable, noninvasive, affordable and safe neuroimaging devices.
